powered by StockChartsAI.com

All Charts and Prices Based on Previous Days Close



Enter Stock Symbol to View AI powered Stock Chart

By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.

Sarepta Therapeutics Inc (SRPT)

Industry: Biotechnology

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.

Sarepta Therapeutics, Inc Website

Instituions

Institution %: 90.055

YTD Institution change: 4406672

Insiders

Insiders %: 4.279

Insiders Purchases YTD: 120071

Insiders Sales YTD: 15000

Insiders Net YTD: 105071

Analyst Ratings

Target Price: 180.61

Overall Rating: 4.3478

Strong Buys (5): 12

Buys (4): 7

Holds (3): 4

Sells (2): 0

Strong Sells (1): 0


Technicals

52 Week Hi: 159.89

52 Week Low: 55.25

Beta: 0.927

50 Day MA: 113.0164

200 Day MA: 111.7646

Earnings / Revenue Trends

Qtr Earnings Growth YOY: 0

Qtr Revenue Growth YOY: 0.441

Forward PE:

Trailing PE: